Transcriptional and Post-translational Dysregulation of SERCA in Type 2 Diabetes

2 型糖尿病中 SERCA 的转录和翻译后失调

基本信息

项目摘要

DESCRIPTION (provided by applicant): At the time of diagnosis, a patient with Type 2 Diabetes Mellitus (T2DM) is estimated to have lost nearly 50% of his or her 2 cell function. Moreover, large prospective studies like the UKPDS, demonstrate that islet function declines continuously throughout the course of this disease. The long-range objective of this applicant is to define the biochemical and epigenetic pathways that govern gene expression and cellular function in the pancreatic 2 cell in order to identify key sites of dysregulation in the pathological state of T2DM. Insulin release from the 2 cell occurs through a Ca2+ dependent mechanism that couples cellular depolarization with intracellular Ca2+ influx from voltage-gated Ca2+ channels, and insulin granule exocytosis. The maintenance of intracellular calcium homeostasis is dependent on adequate sarco-endoplasmic reticulum Ca2+ ATPAse (SERCA) gene expression, protein levels, and protein activity. Preliminary and published studies show that islets from diabetic mice manifest striking changes in SERCA mRNA and protein levels. Further, data from the cardiovascular literature suggests that SERCA is highly susceptible to nitration, oxidation, and degradation under inflammatory conditions. The hypothesis underlying this proposal is that the hyperglycemic and cytokine enriched milieu of diabetes leads to dual insults that alter SERCA2 gene expression and protein activity, which have profound downstream effects on islet calcium homeostasis and islet secretory function. To test this hypothesis, two specific aims are proposed. In Aim 1, the transcriptional regulation of the SERCA2 gene in Type 2 diabetes will be characterized. Experiments will be performed to identify transcriptional cofactors for SERCA2 gene transactivation and to define the epigenetic pathways that govern SERCA2 expression in the islet. In Aim 2, the post-translational regulation of SERCA2 activity in T2DM will be systematically characterized through experiments designed to correlate the development of irreversible inactivating post- translational modifications of SERCA2 protein with endoplasmic reticulum Ca2+ levels and islet secretory function. PUBLIC HEALTH RELEVANCE: Type 2 diabetes mellitus is a disorder of glucose homeostasis caused by a combination of insulin resistance and progressive dysfunction of the insulin producing 2 cells of the pancreas. The incidence of Type 2 diabetes mellitus is increasing dramatically in our society. The research proposed in this application will improve our understanding of the pathogenesis of Type 2 diabetes and inform the development of new treatment strategies for this disease that focus on the preservation of 2 cell function.
描述(由申请人提供):

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regenerative therapeutic potential of adipose stromal cells in early stage diabetic retinopathy.
早期糖尿病性视网膜病中脂肪基质细胞的再生治疗潜力。
  • DOI:
    10.1371/journal.pone.0084671
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Rajashekhar G;Ramadan A;Abburi C;Callaghan B;Traktuev DO;Evans-Molina C;Maturi R;Harris A;Kern TS;March KL
  • 通讯作者:
    March KL
High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling.
  • DOI:
    10.2337/db13-0645
  • 发表时间:
    2013-11
  • 期刊:
  • 影响因子:
    7.7
  • 作者:
    So WY;Cheng Q;Chen L;Evans-Molina C;Xu A;Lam KS;Leung PS
  • 通讯作者:
    Leung PS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Carmella Evans-Molina其他文献

Carmella Evans-Molina的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Carmella Evans-Molina', 18)}}的其他基金

β cell miRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis
β 细胞 miRNA 作为 1 型糖尿病发病机制的分子中心
  • 批准号:
    10561855
  • 财政年份:
    2022
  • 资助金额:
    $ 7.62万
  • 项目类别:
β cell miRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis
β 细胞 miRNA 作为 1 型糖尿病发病机制的分子中心
  • 批准号:
    10321295
  • 财政年份:
    2021
  • 资助金额:
    $ 7.62万
  • 项目类别:
Control of beta cell function and survival by RYR2-mediated calcium signals
通过 RYR2 介导的钙信号控制 β 细胞功能和存活
  • 批准号:
    10491304
  • 财政年份:
    2021
  • 资助金额:
    $ 7.62万
  • 项目类别:
β cell miRNAs Function as Molecular Hubs of Type 1 Diabetes Pathogenesis
β 细胞 miRNA 作为 1 型糖尿病发病机制的分子中心
  • 批准号:
    10615586
  • 财政年份:
    2021
  • 资助金额:
    $ 7.62万
  • 项目类别:
Control of beta cell function and survival by RYR2-mediated calcium signals
通过 RYR2 介导的钙信号控制 β 细胞功能和存活
  • 批准号:
    10375087
  • 财政年份:
    2021
  • 资助金额:
    $ 7.62万
  • 项目类别:
Control of beta cell function and survival by RYR2-mediated calcium signals
通过 RYR2 介导的钙信号控制 β 细胞功能和存活
  • 批准号:
    10689291
  • 财政年份:
    2021
  • 资助金额:
    $ 7.62万
  • 项目类别:
Indiana University clinical Center for acute pancreatitis and diabetes clinical research network
印第安纳大学急性胰腺炎和糖尿病临床中心临床研究网络
  • 批准号:
    10458720
  • 财政年份:
    2020
  • 资助金额:
    $ 7.62万
  • 项目类别:
Indiana University clinical Center for acute pancreatitis and diabetes clinical research network
印第安纳大学急性胰腺炎和糖尿病临床中心临床研究网络
  • 批准号:
    10673629
  • 财政年份:
    2020
  • 资助金额:
    $ 7.62万
  • 项目类别:
Indiana University clinical Center for acute pancreatitis and diabetes clinical research network
印第安纳大学急性胰腺炎和糖尿病临床中心临床研究网络
  • 批准号:
    10265585
  • 财政年份:
    2020
  • 资助金额:
    $ 7.62万
  • 项目类别:
Islet Core
胰岛核心
  • 批准号:
    9105738
  • 财政年份:
    2016
  • 资助金额:
    $ 7.62万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 7.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 7.62万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 7.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了